Oncogene

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2023 CHALLENGE AWARDS TOTALING MORE THAN $21 MILLION FOR PROSTATE CANCER RESEARCH

Retrieved on: 
Thursday, March 14, 2024
University of Illinois Urbana-Champaign, PCF, University of Sydney, Prostate cancer, Genetic testing, Immunotherapy, Prostate Cancer Foundation, Lund University, Oncogene, Patient, PET, Biomarker, Research, Aircraft pilot, University, Doctor of Philosophy, Biology, MBA, MPH, Johns Hopkins University, Institute of Cancer Research, CBP, University of Pretoria, PSMA, Medical imaging

LOS ANGELES, March 14, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2023 Class of PCF Team Challenge Award recipients and a total of more than $21 million in funding for innovative prostate cancer research.

Key Points: 
  • LOS ANGELES, March 14, 2024 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2023 Class of PCF Team Challenge Award recipients and a total of more than $21 million in funding for innovative prostate cancer research.
  • PCF Challenge Awards fund international, multi-institutional, cross-disciplinary teams of investigators conducting highly innovative research with the greatest potential for accelerating new and improved treatments for advanced prostate cancer.
  • Following a rigorous peer review process that assessed each project's scientific merit and potential patient impact, 20 highly coveted PCF Challenge Awards totaling $21.3 million were granted to teams at some of the world's leading cancer research institutions.
  • (Evaluating the impact of treatment with darolutamide on age-related outcomes in vulnerable, older patients with metastatic hormone-sensitive prostate cancer.)

Dominari Securities LLC Expands Investment Banking Practice with Appointment of Experienced Financial Executive

Retrieved on: 
Tuesday, March 12, 2024
Biochemistry, MSRB, McGill University, Medical research, Research fellow, Health, Oncogene, FDIC, Karolinska Institute, Research, CRS, Investment Banking Exam, Investment banking, Senior, Virology, Investment, Breast cancer, Mission, FINRA, SIPC, Security (finance)

NEW YORK, March 12, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has appointed Dr. Cosme Ordoñez to the role of Head of Investment Banking, Investment Banking Principal and bolstering the firm's coverage in the healthcare sector.

Key Points: 
  • Mr. Kyle Wool, CEO of Dominari Securities LLC, commented, "We are thrilled to welcome Cosme to the firm to head up our investment banking practice.
  • Securities Brokerage and Registered Investment Adviser Services are offered through Dominari Securities LLC, a Member of FINRA, MSRB and SIPC.
  • You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at https://brokercheck.finra.org .
  • Information for Dominari Securities LLC and its registered investment professionals as well as its SEC Form CRS may also be found on FINRA's BrokerCheck site.

International Team Led by CHOP Cancer Expert Receives Multimillion Dollar Grant for Childhood Cancer Research from Cancer Grand Challenges

Retrieved on: 
Wednesday, March 6, 2024
Survivor, Oncogene, Ewing sarcoma, Doctor of Philosophy, Neoplasm, Cancer Research UK, Hospital, Neuroblastoma, Child, National Cancer Institute, Medulloblastoma, University, Therapy, KiKa, Protein, CHOP, Survival, Pediatrics, Team, Fibrolamellar hepatocellular carcinoma, Rhabdomyosarcoma, Partnership, Pharmaceutical industry

PHILADELPHIA, March 6, 2024 /PRNewswire/ -- An interdisciplinary, global team of scientists led by Yael Mossé, MD, Professor of Pediatrics in the Cancer Center at Children's Hospital of Philadelphia (CHOP), has been selected as one of five research teams from all over the world to receive funds from Cancer Grand Challenges, a funding initiative co-founded by the National Cancer Institute and Cancer Research UK. Mossé's international team will receive up to $25 million to develop transformative new therapies for previously undruggable forms of childhood cancer.

Key Points: 
  • Mossé's international team will receive up to $25 million to develop transformative new therapies for previously undruggable forms of childhood cancer.
  • Last year, 176 global teams submitted bold ideas for tackling some of the most pressing challenges in cancer research and care.
  • The National Cancer Institute and Cancer Research UK, the world's leading funders of cancer research, co-founded and launched the Cancer Grand Challenges initiative in 2020.
  • In addition to the Team KOODAC3 award, Team MATCHMAKERS, which includes Dr. Nikolaos G. Sgourakis from CHOP, also received a Cancer Grand Challenges award of up to $25 million.

Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program®

Retrieved on: 
Tuesday, January 30, 2024
Partnership, MYB, RNA, Oncogene, Therapy, Leukemia & Lymphoma Society, Patient, LLS, Leukemia, Bone marrow, TAP, CSO

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy Acceleration Program® (TAP) portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company's therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy Acceleration Program® (TAP) portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company's therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.
  • "We are honored by the support and recognition of LLS's Therapy Acceleration Program.
  • LLS's strategic investment in Rgenta continues to bolster our confidence in the potential of our pipeline of oral, small-molecule RNA-targeting medicines," commented Simon Xi, Ph.D., CEO of Rgenta.
  • "We look forward to tapping into the extensive clinical expertise and resources from LLS to accelerate the development of our RNA-targeting MYB inhibitor molecules."

GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia

Retrieved on: 
Thursday, January 11, 2024
Oncogene, FTD, MYC, Patient, Therapy, Accelerated approval (FDA), Acute myeloid leukemia, Venetoclax, Food and Drug Administration, ODD, Azacitidine, Food, MCL1, NDA, Safety, Priority review, FDA, BLA, Marketing, AML, Bone marrow, PTCL, CDK9, Pharmaceutical industry

GFH009 (highly selective CDK9 inhibitor) so far has received both fast track and orphan drug designations from the FDA for the treatment of adult patients with relapsed/refractory (r/r) peripheral T-cell lymphomas (PTCL) and r/r acute myeloid leukemia (AML).

Key Points: 
  • GFH009 (highly selective CDK9 inhibitor) so far has received both fast track and orphan drug designations from the FDA for the treatment of adult patients with relapsed/refractory (r/r) peripheral T-cell lymphomas (PTCL) and r/r acute myeloid leukemia (AML).
  • Numerous subjects in GFH009 studies achieved complete or partial responses, and superior safety profile & efficacy of GFH009 was observed in previous studies.
  • GenFleet is conducting a multi-center, open-label, single-arm study of GFH009 for the treatment of r/r PTCL in close to 40 sites in China.
  • GFH925 was granted with NDA acceptance, priority review and two breakthrough therapy designations in China; GFH009 received FDA fast track and orphan drug designations for two indications.

Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 14, 2023
ASH, ADC, EMA, Patient, Camptothecin, Research, Therapy, Cancer, Oncogene, Poster, Multiple myeloma, Hematology, PALO, Safety, Therapeutic index, IND, DLBCL, Prednisone, Mantle cell lymphoma, Tumor microenvironment, SMDC, Society, RNA, Venetoclax, Corporation, Spacecraft, SME, Salivary gland tumour, MCL1, Cohort, European Medicines Agency, PDX, B-cell lymphoma, University, HER2, Acute lymphoblastic leukemia, Myelodysplastic syndrome, PTCL, MYC, MCL, Neoplasm, CPT, Peripheral T-cell lymphoma, Small and medium-sized enterprises, CDK9, FDA, RNA polymerase II, NIH, Toxicity, Vaccine, Pharmaceutical industry, Fine chemical, Medical imaging, Rare-earth element, Cryptocurrency

PALO ALTO, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • “We continue to take a very disciplined approach to our portfolio, focusing our resources on our two lead programs, VIP943 and VIP236.
  • We will present new data on robust preclinical activity at the 65th American Society for Hematology Meeting (ASH 2023) in December.
  • Collaborators from the University of Calgary will present a poster at ASH 2023 showing preclinical activity in pediatric leukemia.
  • For the quarter ended September 30, 2023, Vincerx reported a net loss of approximately $9.7 million, or $0.46 per share, compared to a net loss of approximately $16.9 million, or $0.80 per share, for the quarter ended September 30, 2022.

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Retrieved on: 
Tuesday, November 7, 2023
MTD, University College London, US, Maxima and minima, Doctor of Philosophy, Index, Orphan, ClinicalTrials.gov, GI/GU, Clinical trial, Oncogene, University College London Hospitals NHS Foundation Trust, Cancer, Pancreatic cancer, TD2, Safety, Therapy, Patient, Oncology, Pharmaceutical industry, Q4

It was discovered by Dr. Stephen Neidle’s team at the University College London and exclusively licensed by Qualigen in January 2021.

Key Points: 
  • It was discovered by Dr. Stephen Neidle’s team at the University College London and exclusively licensed by Qualigen in January 2021.
  • Qualigen received Orphan Drug Designation for the intended treatment of pancreatic cancer in January and clearance from the US FDA to initiate a Phase 1 clinical trial in July of this year.
  • Qualigen anticipates providing an update on safety and preliminary efficacy of the Phase 1a study in the first half of 2024.
  • For more information on QN-302 or the Phase 1a clinical trial, please visit our QN-302 clinical trial website on ClinicalTrials.gov.

Recent Nature publications highlight the groundbreaking performance of RareCyte's Orion Spatial Biology platform

Retrieved on: 
Tuesday, September 26, 2023
University, CRC, Progression-free survival, MSS, Survival, Liquid biopsy, NewYork-Presbyterian Hospital, Research, Harvard Medical School, CLIA, Massachusetts General Hospital, Professor, Publication, Patient, Colorectal cancer, Weill Cornell Medicine, Neoplasm, Hospital, Oncogene, University of Sydney, Recurrence, Neoadjuvant therapy, Medical imaging, Nature, Nature Cancer

SEATTLE, Sept. 26, 2023 /PRNewswire/ -- In the exciting, growing field of Spatial Biology, the Orion platform from RareCyte has emerged as the platform of choice across biomarker discovery, translational and clinical research.

Key Points: 
  • SEATTLE, Sept. 26, 2023 /PRNewswire/ -- In the exciting, growing field of Spatial Biology, the Orion platform from RareCyte has emerged as the platform of choice across biomarker discovery, translational and clinical research.
  • Recent publications of pioneering findings in Nature journals, by leading translational and clinical institutions using the Orion multiplex imaging platform, demonstrate improved methods to help predict patient outcomes and to track the efficacy of novel therapies designed to shrink tumors ahead of resection.
  • Automated generation and ranking of spatial biomarkers revealed novel markers that are highly predictive of progression-free survival.
  • The global adoption of Orion for spatial biology research is a continuation of RareCyte's legacy of supporting important studies across all therapeutic areas, with a special focus on oncology.

Debiopharm Recognizes Pioneering Japanese Cancer Research During the 82nd JCA-Mauvernay Award Ceremony

Retrieved on: 
Tuesday, September 26, 2023
Oncology, Health, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, JCA, Pancreatic cancer, Brain, Senior, Neoplasm, Oxaliplatin, Cancer, Mutation, Innovation, Infection, Biomedical Research, Medulloblastoma, Oncogene, Glioblastoma, Messenger, Liver cancer, Serine/arginine-rich splicing factor 1, Protein, Japanese Cancer Association, Translational research, Patient, Evaluation, CHF, Gene, Safety, Pharmaceutical industry, Debiopharm

This prestigious award honored remarkable and breakthrough Japanese oncology research in two categories: Innovative and/or Disruptive Research – Dr. Daichi Inoue and Translational Research – Dr. Hiromichi Suzuki.

Key Points: 
  • This prestigious award honored remarkable and breakthrough Japanese oncology research in two categories: Innovative and/or Disruptive Research – Dr. Daichi Inoue and Translational Research – Dr. Hiromichi Suzuki.
  • “We have a strong ambition to support Japanese oncology research in becoming new therapies for cancer patients that need them.
  • This award was inspired by our previous success with the development of oxaliplatin, a standard-of-care now commercialized worldwide to treat metastatic colorectal cancer, pancreatic cancer and liver cancer.
  • Since 2005, the Japanese Cancer Association (JCA) and Debiopharm have co-organized the 'JCA-Mauvernay Award'.

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Retrieved on: 
Monday, June 26, 2023
Immortalised cell line, Marker, Antigen, DNA, PI, ARTEMIS, Survivin, SBIR, Majesty of the Seas, HMA, Clinical trial, NIH, Gene expression, Cell, HSCT, Bangladesh Technical Education Board, Oncogene, PRAME, Acute myeloid leukemia, THP-1 cell line, Trial of the century, AML, THP-1, Patient, Small Business Innovation Research, WT-1, Wong, DNA methylation, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DMSO, Food, Safety, Bone marrow, Pharmaceutical industry, Vaccine, Decitabine

MT-401 was designed to specifically target four different antigens (Survivin, PRAME, WT-1 and NY-ESO-1), which are upregulated in AML but have limited expression on normal cells.

Key Points: 
  • MT-401 was designed to specifically target four different antigens (Survivin, PRAME, WT-1 and NY-ESO-1), which are upregulated in AML but have limited expression on normal cells.
  • Given the promising responses in patients who are MRD+, Marker has been investigating clinical opportunities to further improve AML patient outcomes.
  • One such opportunity is to combine multiTAA-specific T cell therapy with agents that make cancer cells more visible to cancer killing cells.
  • These in vitro data demonstrate that administration of MT-401 following HMA infusion enhanced AML cell killing and could offer a new therapeutic option for AML patients post-HSCT.